Publications & Presentations

January 24, 2022

PresentationTivozanib

ASCO GI 2022: A Phase 1b/2 Open Label Study of Tivozanib in Combination with Durvalumab in Subjects with Advanced Hepatocellular Carcinoma: DEDUCTIVE

January 24, 2022

PresentationTivozanib

ASCO GI 2022: A Phase 1b/2 Study of Tivozanib in Combination with Durvalumab in Subjects with Advanced Hepatocellular Carcinoma (DEDUCTIVE): Efficacy Results in Previously Untreated Patients

September 1, 2021

PublicationFiclatuzumab

Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis

Authors: Victoria E. Wang, Bradley W. Blaser, Ravi K. Patel, Gregory K. Behbehani, Arjun A. Rao, Blythe Durbin-Johnson, Tommy Jiang, Aaron C. Logan, Matthew Settles, Gabriel N. Mannis, Rebecca Olin, Lloyd E. Damon, Thomas G. Martin, Peter H. Sayre, Karin M. Gaensler, Emma McMahon, Michael Flanders, Vivian Weinberg, Chun J. Ye, David P. Carbone, Pamela N. Munster, Gabriela K. Fragiadakis, Frank McCormick, Charalambos Andreadis. Click here for link to article.

June 4, 2021

PresentationFiclatuzumab

ASCO 2021: Randomized Phase II Trial of Ficlatuzumab with or without Cetuximab in Pan-Refractory, Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

June 4, 2021

PresentationTivozanib

ASCO 2021: TIVO-3: Durability of Response and Updated Overall Survival of Tivozanib vs Sorafenib in Metastatic Renal Cell Carcinoma (mRCC)

June 4, 2021

PresentationTivozanib

ASCO 2021: Temporal Characteristics of Treatment-Emergent Adverse Events and Dose Modifications With Tivozanib and Sorafenib in the Phase 3 TIVO-3 Study of Relapsed or Refractory mRCC